Form 4: Cocrystal Pharma Director Boosts Stake

Phillip Frost, a Director and 10% Owner of Cocrystal Pharma, acquired 20,000 shares of common stock at a weighted average price of $0.9406.

Summary

• Phillip Frost, MD, a Director and 10% Owner of Cocrystal Pharma, Inc. (COCP), acquired 20,000 shares of common stock.
• The transaction occurred on November 25, 2025.
• The shares were acquired at a weighted average price of $0.9406 per share, with transactions ranging from $0.937 to $0.943.
• Following this transaction, Frost Gamma Investments Trust indirectly holds 1,699,551 shares.
• Phillip Frost directly holds 27,100 shares, which includes shares issuable upon vesting of restricted stock units.
• The total beneficial ownership reported by Phillip Frost, MD, after the transaction is 1,726,551 shares (1,699,551 indirect + 27,100 direct).

Sentiment

Score: 7

Explanation: The acquisition of shares by a significant insider (Director and 10% Owner) at a specific price generally indicates confidence in the company's future prospects, which is a positive signal for investors.

Positives

• A Director and 10% Owner, Phillip Frost, acquired 20,000 shares of common stock, indicating insider confidence in the company's prospects.
• The acquisition price of $0.9406 per share suggests a belief in the company's value at or above this level by a significant insider.

Related Party Transactions

• The 1,699,551 indirectly held shares are by Frost Gamma Investments Trust, of which Phillip Frost, MD, is the trustee.
• Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust, and Dr. Frost is one of two limited partners of Frost Gamma L.P.
• The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation, of which Dr. Frost is the sole stockholder.
• The filing explicitly excludes securities owned directly by OPKO Health, Inc., where Dr. Frost is Chairman of the Board and Chief Executive Officer, and Dr. Frost disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders may interpret the insider purchase as a positive signal of management's confidence in the company's future, potentially influencing investor sentiment and stock price.
• The transaction demonstrates continued investment by a key director and significant owner in the company's equity.

Key Dates

Recommendation

The acquisition of 20,000 shares by a Director and 10% Owner, Phillip Frost, signals insider confidence in Cocrystal Pharma's valuation at the reported price. While this is a positive indicator, a comprehensive investment decision would require further analysis of the company's financial performance, strategic initiatives, and market conditions beyond the scope of this insider transaction report.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Trading, Stock Acquisition, Form 4, Beneficial Ownership, Director, 10% Owner